2023
DOI: 10.21037/tcr-23-1
|View full text |Cite
|
Sign up to set email alerts
|

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…Despite the use of multimodal therapy, the local-regional recurrence rate for advanced HNSCC can be as high as 50% [6]. Notably, recurrent and metastatic disease emerges as a major cause of mortality in HNSCC [7]. Despite remarkable advances in surgery, radiation, and medical therapy over the past few decades, the prognosis for HN-SCC remains poor, with a 5-year overall survival rate ranging from 25% for hypopharyngeal cancer to 59% for laryngeal cancer [8].…”
Section: Introductionmentioning
confidence: 99%
“…Despite the use of multimodal therapy, the local-regional recurrence rate for advanced HNSCC can be as high as 50% [6]. Notably, recurrent and metastatic disease emerges as a major cause of mortality in HNSCC [7]. Despite remarkable advances in surgery, radiation, and medical therapy over the past few decades, the prognosis for HN-SCC remains poor, with a 5-year overall survival rate ranging from 25% for hypopharyngeal cancer to 59% for laryngeal cancer [8].…”
Section: Introductionmentioning
confidence: 99%